ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
-0.28EPS Dil.
-111.51P/E
8.30BMarket Cap
Legends:
Stock price
0.29
Beta (1.0 Market)
% total return 05/01
Stock
S&P500
YTD
466.79
- -
3Y
287.47
- -
5Y
1,201.25
- -
Capital Structure
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
4
4
4
LT Borrowings
- -
72
72
LT Finance Leases
10
9
8
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
226
249
266
Market Capitalization
868
4,693
4,219
Working Capital
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
244
669
767
Cash, Cash Equivalents & STI
201
572
606
Accounts Receivable, Net
27
75
131
Inventories
1
3
5
Total Current Liabilities
102
94
135
Payables & Accruals
63
55
68
ST Debt
4
4
4
Deferred Revenue
13
14
37
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
0.92
0.94
0.55
0.24
0.28
0.21
0.42
0.70
0.99
0.69
1.18
0.38
0.55
0.75
0.34
0.43
1.10
Revenue per ShareRevenue per Share
-0.45
-0.75
-0.63
-0.87
-0.85
-0.95
-0.87
-0.83
-0.71
-1.67
-0.98
-1.21
-0.70
-0.25
-0.68
-0.88
-0.28
Basic EPS, GAAPBasic EPS, GAAP
-0.43
-0.89
-0.30
-0.72
-0.15
-0.48
-0.76
-0.72
-0.73
-1.55
0.07
-1.23
-0.62
-0.45
-0.83
-0.91
-0.76
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
-6.06
-5.69
-5.63
-5.47
-5.64
-6.47
-6.80
-7.53
-8.18
-9.78
-7.75
-7.91
-8.57
-6.82
-6.67
-7.48
-6.42
Book Value per ShareBook Value per Share
1.38
1.09
1.17
1.50
1.83
1.08
1.44
0.88
0.41
-0.94
-0.14
0.07
-0.51
0.46
1.48
0.69
2.11
Tangible Book Value per ShareTangible Book Value per Share